

Characterization and validation of regional variation in fibrosis within traditional fibrosis stages

Contact information Elaine.Chng@histoindex.com

¹Histoindex Pte. Ltd., Singapore, ²Virginia Commonwealth University School of Medicine, Richmond, Virginia, United States, ³Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States., ⁴Stravitz-Sanyal Institute of Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond, United States

Introduction

- Histological assessment has anchored the field of metabolic dysfunction associated steatotic liver disease (MASLD) as a measure of the "ground truth".
- However, variability in human staging of fibrosis has driven the development of digital pathology approaches to improve the fidelity of the histological assessments.
- Second harmonic generation/two-photon excitation fluorescence (SHG/TPEF) imaging is such a method which generates a quantitative fibrosis (qF) score and has provided deep insights into regional differences in fibrosis evolution and during resolution in MASH.

Aim

- The current study represents an independent validation of this method by the NIDDK NASH Clinical Research Network (CRN).
- The analysis will delineate the changes in collagen components observed in baseline biopsies across different stages of the disease and aims to identify specific patterns or alterations in collagen that correlate with the baseline disease stage.

Method

- A curated set of 100 paired liver biopsies, separated by a median of 4 years, was selected from the NASH CRN histological database. Of these, 45% demonstrated fibrosis progression, 10% showed no change, and 45% exhibited regression.
- SHG/TPEF imaging was performed. Overall qF scores and zonal qF scores (zones 1, 2, 3, central vein, and portal areas) were also independently reported.
- Image-based tissue qualification criteria are applied before proceeding to image analysis which include:
 - No. of Central Veins (CV) > 2
 - No. of Portal Tracts (PT) > 5
 - Biopsy Length > 10 mm İİİ.
 - Average width > 0.5 mm
 - Percentage of fragmentation < 50%
- A prespecified statistical plan and strict data chain of custody ensured study integrity and independence.
- Concordance with conventional fibrosis staging and zonal changes are assessed as part of a cross-sectional analysis by stage in the baseline biopsies.



Elaine Chng¹, Ekaterina Smirnova², Julian Lee¹, Dean Tai¹, David E. Kleiner³, Arun J. Sanyal⁴

to different clinical outcomes.

NASH CRN fibrosis stage No fibrosis 1C periportal Bridging fibrosis Cirrhosis



- Heatmaps of the portal, zones 1 and 2 show the trend of how fibrosis components evolve with fibrosis stage
- The big change in zone 3 (pericentral region) occur from F0 to F1, and not much changes after, reflecting reality of early perisinusoidal fibrosis development in zone 3.

Subsequent analyses on the follow-up biopsies will evaluate the prognostic significance of these specific qFibrosis parameters in relation

